Introduction
Lung cancer is the most common cancer type in the World currently. According to Globocan 2012 data published by International Cancer Agency (IARC) 14.067.894 cancer cases were diagnosed worldwide and lung cancer formed 13% of those cases (1.824.701) (1) . In Turkey, according to data by T.R. Ministry of Health, Administration of Public Health, Department of Cancer, lung cancer incidence is at 1 st order in males and at 4 th order in females (2) . Lung cancer is divided into two groups histologically: non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (3, 4) . SCLC is the most aggressive with highest mortality rate and accounts 12-14% of all lung cancer cases (5) . NSCLC is the most commonly encountered lung cancer type and constitutes approximately 80-83% of all cases diagnosed with lung cancer. NSCLC also divided to histological subtypes such as adenocarcinoma, squamous cell carcinoma, large-cell carcinoma and broncoalveolar carcinoma. Among those subtypes, adenocarcinoma is the most common (6) . Formation of lung cancer is related with various environmental and genetic factors (7) . Although patients diagnosed with lung cancer at similar stages and histological subtypes, they can have great differences in their prognosis. Those differences may be related with increase or decrease of some proteins (ex. proteins counterpart in coagulation) which are not directly related with cancer formation (8) .
Fibrinogen is a glycoprotein synthesized in hepatocyte cells with a molecular weight of 350 KD (9) . Fibrinogen is formed of two sets of alpha, beta and gamma polypeptide chains which are attached to each other with disulfide bridges (10) . Thrombin transforms fibrinogen to water insoluble fibrin which has a role in coagulation, inflammatory response, fibrinolysis and wound healing (10) . Three polypeptides forming fibrinogen is coded in q23-32 arm of 4 th 161 chromosome. Various polymorphisms were determined on gene performing fibrinogen synthesis. Among those polymorphisms, β chain polymorphisms are studies extensively since β chain is the time limiting step in adult fibrinogen synthesis (11) . Nucleotide transition (-455G/A) at -455 position of the promoter region of β-fibrinogen gene increases plasma fibrinogen level (12) . There are many studies revealing the relationship between high plasma fibrinogen concentration and angiogenesis, proliferation and metastasis of tumor cells (13) . In studies concerning relationship between lung cancer and enhanced fibrinogen concentration, high plasma fibrinogen concentration is suggested as an important marker for tumor metastasis and patient prognosis (8, 14 Measurements were conducted in microplate reader at 450 nm wavelength (Bio-Tek PowerWave XS). For the kit intra-assay variation coefficient was 5.1%, inter-assay variation coefficient was 7.5% and minimum detectable value was 0.16 µg/ml. Results were presented as g/l. In addition according to instructions given in kit, 1.5-4 g/l range was defined as normal fibrinogen concentration whereas >4 g/l was defined as hyperfibrinogenemia. Statistical Analysis: Statistical analysis of data was performed by using IBM-SPSS 19.0 statistical program. Distribution of variables was checked via Kolmogorov-Smirnov test. Normal distribution of numeric variables were found and sample-T test was used for statistical analysis of difference between variables in two groups. For assessment of difference of variables in three and more groups One-way-ANOVA test was used. For the analysis of categorical data X 2 (Chi-square) test was used. P<0.05 value was accepted as statistically significant. (Figure 4 ). When patients with lung cancer are divided into two groups as NSCLC and SCLC and assessed for fibrinogen values no statistically significant difference was detected (5.36±1.14 and 5.04±0.81 respectively, p>0.05) ( Figure 5 ).
Discussion
Lung cancer is a type of cancer with highest morbidity and mortality rates worldwide (18) . Although lung cancer is directly related with tobacco and tobacco products or with exposure, genetic factors have an important role (19) . Those differences may be related with increase or decrease of some proteins (ex. proteins counterpart in coagulation) which are not directly related with cancer formation. It has been known for 150 years that haemostatic factors have a role in cancer etiopathogenesis (20) . Various haemostatic anomalies such as intravascular coagulation, hemorrhagic events and migratory tromboflebitis occur in cancer patients. Such haemostatic anomalies are placed in second order as cause of death (21, 22) . Many coagulation abnormalities are reported for cancer patients. Augmented fibrinogen activity is among them (23) . Studies concerning fibrinogen which is a coagulation factor and cancer, augmented fibrinogen activity was found to affect tumor cell growth, progression and metastasis (23) . Hyperfibrinogenemia is found related with colorectal (24), cervical (25) , over (26) , esophagus (27) and pancreas (28) cancer types and found to increase in such cancer types. Guo et al (28) found an increase in serum fibrinogen level in pancreas cancer patients and also showed increased risk for distal metastasis in patients with high fibrinogen level after follow-up those patients. There (29) determined serum fibrinogen levels in 21 lung cancer, 5 hepatic cancer, 8 stomach cancer, 16 colon cancer and a total of 139 cases diagnosed with cancer and compared with healthy control group. As a result, they found that the fibrinogen levels of patients with lung cancer were higher than both control and the mean of all cancer patients. Result obtained in our study was supporting results of previous studies. Fibrinogen levels in patients with lung cancer were statistically significantly higher compared to observed values in healthy control group. In addition, when we divided our patient group into two groups as NSCLC and SCLC and checked for fibrinogen levels, hyperfibrinogenemia was observed in both of the groups. Fibrinogen levels in NSCLC patients were higher than SCLC patients however we observed that this rise was not statistically significant. Many physiological and pathological reasons may exist for this rise. However, we couldn't encounter any literature focusing on this rise in fibrinogen concentration in lung cancer patients is related with genetic origin in our literature search. In our study we have investigated -455 G/A polymorphism since A allele causing this polymorphism is found about 20% of adult population and affects fibrinogen concentration directly (30) . In the case of A allele homozygosity which is observed in about 1-5% of population, fibrinogen levels were augmented, whereas in G allele homozygosity or heterozygosity no difference was observed in fibrinogen concentration in our study.
Results obtained in our study are in consistence with literature records. In both patients with lung cancer and healthy control group, group bearing AA genotype had statistically significantly higher fibrinogen levels than group bearing GG and GA genotypes.
There are two studies focusing on -148 C/T and gama-10034 C/T polymorphisms in colorectal cancer patients. Vossen et al. (31) in their study, investigated protrombine G20210A, PAI-1 4G/5G, MTHFR 677 C/T, factor XIII Val34Leu and gamma-fibrinogen 10034 C/T polymorphisms in 1801 patients with colorectal disease and 1853 healthy control group. As a result, they have detected, 978 CC allele bearing, 656 CT allele bearing and 103 TT allele bearing colorectal cancer patients were determined according to their obtained gamma-fibrinogen 10034 C/T. Finally, they have found no relationship between colorectal cancer risk and evaluated polymorphisms including gammafibrinogen 10034 C/T polymorphism. Wang et al.
investigated β-fibrinogen -144C/T polymorphism in patients with colorectal cancer and found no difference between cancer and healthy group in T allele frequency which causes increase in fibrinogen concentration. In our study in 59 of patients (59%) with lung cancer GG, in 32 (32%) GA and in 9 (9%) AA genotypes were found. Similarly in analysis performed on healthy group in 59 individuals (59%) GG, in 33 (33%) GA and in 8 (8%) AA genotypes were determined. No difference was found between patients with lung cancer and healthy control group for β-fibrinogen -455G/A polymorphism. When patients with lung cancer were grouped according to GG, GA and AA genotypes and assessed for their fibrinogen levels, group bearing AA genotype had fibrinogen level significantly higher than two other groups but fibrinogen level of all groups were higher than 4 g/l (hyperfibrinogenemia). In the healthy control group, group bearing AA genotype had fibrinogen level higher than two other groups however group bearing GG and GA genotypes had fibrinogen mean lower than 4 g/L. According to these results, β-fibrinogen -455G/A polymorphism can be considered as nonrelated with lung cancer formation and prognosis. In addition, it can be stated that it is nonrelated with rise of fibrinogen levels in patients with lung cancer. Patients with lung cancer were divided into groups with NSCLC and SCLC histologically and β-fibrinogen -455 G/A polymorphism was investigated. GG genotype detected in 59% of patients with lung cancer was found 29% in SCLC and 71% in NSCLC. In addition, GA genotype detected in patients with lung cancer was found 25% in SCLC and 75% in NSCLC. Also AA genotype detected in patient group was found 66.6% in SCLC and 33.7% in NSCLC. When frequencies of A and G alleles were investigated, A allele frequency was found statistically significantly higher in SCLC. In SCLC patients with high A allele frequency, fibrinogen levels were found higher than NSCLC patients, but it was not statistically significant. According to this data, A allele was suggested to have a role in prognosis of SCLC which is a more aggressive form of lung cancer with lower life expectance however a study with a wider population is needed to clearly interpret this situation. ACE is an important enzyme found in reninangiotensin system (RAS) (33) . This enzyme has an important role in vascular homestasis modulation, inflammation, and angiogenesis (34) . ACE is synthesized in various tissues and mainly in lung, liver, heart and testis (35) . There are studies showing detoriation of ACE activity in some cancer types (36) (37) (38) . ACE I/D polymorphism is evaluated in patients with lung cancer by many researchers and contradictory results were obtained. Nacak et al. (39) investigated ACE I/D polymorphism in 125 lung cancer patients and in 165 healthy control group, and found higher I allele frequency in patient group. According to this result, Nacak As a result, it is possible to state that β-fibrinogen -455 G/A and ACE I/D polymorphisms are not related with formation and prognosis of lung cancer and no genetic susceptibility to lung cancer is found in persons bearing these polymorphisms. In addition increase in fibrinogen level in patients with lung cancer is not probably caused by genetic origin.
